Autoantibody reactome analysis reveals diagnostic biomarkers and molecular classification for relapsing polychondritis.

Journal: Annals of the rheumatic diseases
Published Date:

Abstract

OBJECTIVES: The lack of effective biomarkers for relapsing polychondritis (RP) poses a significant challenge in its early diagnosis and treatment. This study aimed to identify novel autoantibodies and elucidate the pathogenesis and molecular heterogeneity of RP.

Authors

  • Yongmei Liu
    Institute of Systems Genetics, Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610000, China.
  • Mengzhu Zhao
    Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Key Laboratory of Rheumatology and Clinical Immunology, Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China.
  • Lei Zhang
    Division of Gastroenterology, Union Hospital, Tongji Medical College Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Jing Luo
    Department of Ophthalmology, The Second Xiangya Hospital of Central South University, 139 Middle Renmin RD, Changsha, Hunan, China.
  • Linlin Cheng
    Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
  • Haoting Zhan
    Department of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
  • Mansheng Li
    State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Science-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.
  • Zijuan Zhang
    Department of Pathology, State Key Laboratory of Complex Severe and Rare Diseases, Molecular Pathology Research Centre, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Siyu Wang
    School of Nursing, Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu, 610075, China. Electronic address: 919008390@qq.com.
  • Xinxin Feng
    Department of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
  • Min Feng
    Laboratory of Pathology Key Laboratory of Transplant Engineering and Immunology NHC, West China Hospital Sichuan University Chengdu China.
  • Haolong Li
    Department of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
  • Zhan Li
    School of Information Science and Technology, Northwest University, 710127, Xi'an, China. Electronic address: lizhan@nwu.edu.cn.
  • Jingdi Zhang
    School of Pharmacy, Hengyang Medical College, University of South China, Hengyang, China.
  • Yong Hou
    BGI-Shenzhen, Shenzhen 518083, China.
  • Xiaobo Yu
    State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Science-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.
  • Yongzhe Li
    School of Nuclear Science and Technology, University of Science and Technology of China, Hefei, 230026, China.

Keywords

No keywords available for this article.